Connection
Janet Rader to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Janet Rader has written about Neoplasm Recurrence, Local.
|
|
Connection Strength |
|
|
|
|
|
0.969 |
|
|
|
-
Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul; 130(1):64-8.
Score: 0.328
-
Dudzinski MR, Rader JS. The mons pubis: an excellent graft donor site in gynecologic surgery. Am J Obstet Gynecol. 1990 Mar; 162(3):722-5.
Score: 0.066
-
Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, Siegel BA, Grigsby PW. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009 Jan; 112(1):104-9.
Score: 0.060
-
Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73.
Score: 0.060
-
Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 2007 Sep-Oct; 27(5B):3525-8.
Score: 0.056
-
Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008 May-Jun; 18(3):400-6.
Score: 0.055
-
Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
Score: 0.051
-
Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
Score: 0.051
-
Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01; 43(5):527-534.
Score: 0.044
-
Armstrong DK, Blessing JA, Rader J, Sorosky JI. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs. 2003 Nov; 21(4):453-7.
Score: 0.043
-
Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4.
Score: 0.038
-
Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep; 66(3):480-6.
Score: 0.028
-
Eng KH, Wang S, Bradley WH, Rader JS, Kendziorski C. Pathway index models for construction of patient-specific risk profiles. Stat Med. 2013 Apr 30; 32(9):1524-35.
Score: 0.020
-
Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, Powell MA, Grigsby PW. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1085-91.
Score: 0.016
-
Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):480-4.
Score: 0.013
-
Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
Score: 0.011
-
Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004 Jun 01; 22(11):2167-71.
Score: 0.011
-
Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer. 2002 Jun 01; 94(11):2941-52.
Score: 0.010
-
O'sullivan MJ, Rader JS, Gerhard DS, Li Y, Trinkaus KM, Gersell DJ, Huettner PC. Loss of heterozygosity at 11q23.3 in vasculoinvasive and metastatic squamous cell carcinoma of the cervix. Hum Pathol. 2001 May; 32(5):475-8.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|